If you live with fibromyalgia, you have probably spent years being told your pain was something other than pain. That you were stressed, or run down, or simply needed to push through it. Maybe you have sat across from a doctor who found nothing on a scan and left the room with the quiet sense that the problem was you rather than your nervous system. So when a study hits the news saying fibromyalgia is genetic, and therefore real, the relief is instant. Finally, something solid to point to.
That study is real, and it is good science. It was published in Nature Medicine in 2026, it drew together data from more than two and a half million people, and it is the largest look at the genetics of fibromyalgia anyone has ever attempted [1]. None of that is the problem. The problem is the headline bolted onto it, the one that read “it’s not in your head, it’s genetic.” Sit down with the actual paper and it says something more interesting, and far more useful, than that headline managed.
This article walks through what the study genuinely found, in plain English. The few numbers that matter, why “genetic” does not mean what the headline wants it to mean, and why the findings sit rather comfortably alongside the way fibromyalgia tends to behave in real life. We are also going to be straight about what the study cannot tell you, because there are a couple of genuine limitations worth keeping in your back pocket. None of this is a takedown. The science is strong. It is about reading the paper properly rather than through a headline writer’s need for a fight.
What the study actually did
The scale is the first thing to take in. The researchers combined data from eleven separate groups of people and ended up with 54,629 people diagnosed with fibromyalgia set against just over 2.5 million without it [1]. For a condition that has spent decades being treated as vague, contested, or not quite real, a genetic study this size is a milestone on its own. A dataset that big lets small signals show up clearly, which matters for everything that follows.
Two details about how it was built matter later, so they are worth flagging now. The fibromyalgia cases were identified from medical records, meaning anyone carrying the diagnostic code for fibromyalgia, rather than from a fresh clinical assessment of each person [1]. And around 90% of the people involved were of European ancestry [1]. Neither of those sinks the study. Both of them shape how far its conclusions can reasonably stretch, and we will come back to each.
The number the headlines skipped: 10.4%
The figure that never made the headline is this one. The study found that common gene variants explain about 10.4% of the risk of developing fibromyalgia, with a tight confidence interval around that number [1]. Read it twice, because it is the whole story in a single line. Common genetic variation accounts for roughly a tenth of the picture. The other ninety per cent sits somewhere else.
That is a real result, and a modest one. Genes nudge the risk and load the dice a little. They do not deal the hand. So the notion that “it’s genetic,” said in the tone that means case closed, was never what the data showed. When it comes to fibromyalgia, common genetic variation is one thread in a much larger weave, not the thing that produces the condition by itself.
There is one honest caveat here, and being precise about it strengthens the point rather than softening it. That 10.4% counts only common gene variants, the kind this sort of study is designed to measure. It is a floor, not a ceiling. Older work on families has long suggested fibromyalgia carries some inherited component, with the condition clustering in close relatives more than chance alone would predict [2]. Even allowing for that, common variants explaining about a tenth of the risk is a long way from “your genes gave you this.” However you account for the rest, the honest reading holds. Genes are part of the story and nowhere near all of it.
The signal lives in the brain
The next finding is the one worth framing. When it comes to where in the body that genetic signal actually sits, it landed almost entirely in a single place. The heritability was, in the authors’ own words, exclusively enriched within brain tissues and neural cell types [1]. Cortex, caudate, frontal cortex, the anterior cingulate. The regions that take signals in, weigh them, and decide how loudly to respond. There was no meaningful signal in immune tissue, which is exactly why the authors say this does not look like a primarily autoimmune condition [1].
For anyone who has read much about how chronic pain works, this will feel familiar. Fibromyalgia behaves like a condition of central sensitisation, where the nervous system becomes steadily more reactive to incoming signals and starts amplifying them well beyond what is happening in the tissues. The clinical name for pain that comes from altered processing in the nervous system, rather than from ongoing tissue damage or a nerve injury, is nociplastic pain [3]. The way I have always put it to people is that the volume knob on the nervous system has been turned up and then jammed there. Ordinary signals come in, get cranked up on the way through, and arrive as pain. A study finding that the genetic signal for fibromyalgia lives in the brain rather than the joints or the immune system fits that picture closely.
The overlap that breaks the headline
This is where the headline properly comes apart. The researchers measured how much fibromyalgia’s genetic architecture overlaps with other conditions, and the overlaps are big. With post-traumatic stress disorder the genetic correlation came in at 0.78. With low back pain, 0.75. With irritable bowel syndrome, 0.70. With depression, 0.63 [1]. Taken together, fibromyalgia shares something close to two-thirds of its genetic wiring with the systems that handle stress, mood and other forms of long-term pain.
Sit with what that does to the headline. A paper being sold as proof that fibromyalgia has nothing to do with psychology is, in its own data, showing the condition is genetically braided into stress and mood. You cannot cleanly separate the two, because at the level of the genes they were never separate. This is not a quirk of one dataset either. Separate genetic work on overlapping pain conditions has reached much the same conclusion, treating nociplastic pain as a heritable trait tied genetically to other chronic pain syndromes [4].
The gene that grabbed the headlines
A word on the gene that did most of the media’s work for it. The single strongest genetic hit in the study sat on a gene called HTT, and if that name is familiar it is the gene involved in Huntington’s disease. A second nearby hit, GPR52, is already being looked at as a drug target for Huntington’s, which is what set off the excited talk about repurposing existing drugs for fibromyalgia [1]. You can see the appeal of that story.
The effect itself is small, as that variant raised the odds of fibromyalgia by around nine per cent, which is a nudge rather than a switch [1]. And here is the part that did not travel into the headlines. When the researchers accounted for the actual Huntington’s-causing mutation, the fibromyalgia signal at that spot essentially vanished [1]. This is not the Huntington’s mutation handing people fibromyalgia. It is an interesting flag on a stretch of DNA that needs a great deal more work before anyone claims a shared mechanism. A lead worth chasing rather than a finding to bank.
Why it hits women harder, and what the genes cannot explain
Fibromyalgia is diagnosed in women far more often than in men, roughly two to three times as often. When it comes to explaining why, though, a genetic study of this size draws a blank, and that blank is genuinely interesting. Comparing the genetic architecture between the sexes, the researchers found it almost identical, with a correlation of 1.03 [1]. Whatever drives the difference in who ends up diagnosed, it is not a different genetic blueprint in men and women.
One honest note sits alongside that. Around 88% of the cases were women, and the analysis in men was much smaller and less powered, turning up only a couple of male-specific signals against twenty-one in women [1]. The picture in men specifically is still thin, so anything said about male fibromyalgia from this data should be treated as early rather than settled.
The limitations worth keeping in your pocket
Two limitations are worth carrying out of this, and the first is the one most likely to trip up a confident reading. Because the cases were pulled from diagnostic codes rather than fresh clinical assessment, some people labelled here as having fibromyalgia may have had something else entirely. Fibromyalgia is a well known catch-all, and conditions such as hypermobility spectrum disorders can be mislabelled as fibromyalgia when the underlying cause is missed [5]. That matters in both directions. It muddies who is actually in the fibromyalgia group, and if a share of those cases were really living with depression, PTSD or IBS, some of the very genetic overlaps we looked at earlier could be inflated by that mislabelling rather than reflecting shared biology. The overlap is too large and too consistent to be an artefact on its own, but it is a reason to hold the exact figures a little loosely.
The second limitation is reach. With around 90% of the sample of European ancestry, the findings speak most confidently about people of European background and less so about everyone else [1]. Genetics does not always transfer neatly from one population to another, and until the work is repeated in more diverse groups, the numbers are best read as a strong start rather than the last word.
So what does this actually mean for you
Strip away the headline fight and the study leaves you with something steadier than the news implied. Fibromyalgia looks like a condition of the central nervous system, with a genetic contribution that is real, modest, and concentrated in the brain rather than the immune system. The pain is not imagined, and it never was. It is the output of a nervous system that has learned to amplify, wired into the same circuitry that handles stress, mood and other kinds of persistent pain.
That is not a bleak conclusion, and it is the part I would most want you to take from it. A condition rooted in how the nervous system processes signals is a condition that can change, because processing can be retrained in a way a broken bone or a torn ligament cannot. It also explains why approaches that work with the nervous system, rather than chasing damage that is not there, tend to be the ones that help. A separate 2025 study made the same point from the other side, finding that biological markers and psychosocial factors together predicted chronic pain far better than either did on its own [6]. Biology and psychology were never opposing teams. They are two hands on the same volume knob.
So back the science, because it is solid and it moves the field forward. Just leave the biology-versus-psychology row where it belongs, which is with the headline writer who invented it. “It’s not in your head” was never the argument worth having. Your pain was always real. What this study adds is a clearer look at the wiring behind it, and a better sense of where the door out actually is.
Frequently asked questions
Is fibromyalgia genetic?
Partly, and only partly. The largest genetic study ever done found that common gene variants explain about 10.4% of the risk of developing fibromyalgia [1]. That is a real genetic contribution, but it leaves the large majority of the picture down to other factors. Genes load the dice a little rather than deciding the outcome, so calling fibromyalgia “a genetic condition” overstates what the evidence actually shows.
Does this study prove fibromyalgia is not “in your head”?
It confirms the pain is real, which was never seriously in doubt among people who understand the condition. What it does not do is separate fibromyalgia from psychology. The same study found the condition shares roughly two-thirds of its genetic architecture with PTSD, depression and other pain conditions [1]. The wiring for pain and the wiring for stress and mood are closely linked, so pitting biology against psychology misreads the data.
What does 10.4% heritability actually mean?
It means common genetic variants, the kind this study measures, account for about a tenth of the differences in who develops fibromyalgia. It is best understood as a floor rather than a ceiling, since family studies suggest some further inherited component that this method does not capture [2]. Either way, it tells you genetics is one contributing factor among many rather than the cause.
Is fibromyalgia an autoimmune disease?
This study argues against that as the primary driver. The genetic signal was concentrated in brain tissue and neural cell types, with no meaningful signal in immune tissue, which led the authors to conclude it does not look like a primarily autoimmune condition [1]. It behaves far more like a disorder of how the nervous system processes signals, known as nociplastic pain [3].
Why does fibromyalgia affect more women than men?
The genes do not explain it. When researchers compared the genetic architecture between the sexes it was almost identical [1], so the two to three times higher rate in women is not down to a different genetic blueprint. The cause of that skew lies somewhere other than common genetics, and this study could not pin it down. The male sample was also much smaller, so findings specific to men remain preliminary.
References
[1] Kerrebijn, I., Bjornsdottir, G., Arbabi, K. et al. (2026) ‘The genetic architecture of fibromyalgia across 2.5 million individuals’, Nature Medicine. doi: 10.1038/s41591-026-04492-6.
[2] Arnold, L.M., Hudson, J.I., Hess, E.V. et al. (2004) ‘Family study of fibromyalgia’, Arthritis & Rheumatism, 50(3), pp. 944-952. doi: 10.1002/art.20042.
[3] Shraim, M.A., Sluka, K.A., Sterling, M. et al. (2022) ‘Features and methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: a Delphi expert consensus study’, Pain, 163(9), pp. 1812-1828. doi: 10.1097/j.pain.0000000000002577.
[4] Johnston, K.J.A., Signer, R. and Huckins, L.M. (2025) ‘Chronic overlapping pain conditions and nociplastic pain’, Human Genetics and Genomics Advances, 6(1), 100381. doi: 10.1016/j.xhgg.2024.100381.
[5] Häuser, W., Perrot, S., Sommer, C., Shir, Y. and Fitzcharles, M.A. (2017) ‘Diagnostic confounders of chronic widespread pain: not always fibromyalgia’, PAIN Reports, 2(3), e598. doi: 10.1097/pr9.0000000000000598.
[6] Fillingim, M., Tanguay-Sabourin, C., Parisien, M. et al. (2025) ‘Biological markers and psychosocial factors predict chronic pain conditions’, Nature Human Behaviour, 9(8), pp. 1710-1725. doi: 10.1038/s41562-025-02156-y.
